HRA Pharma is a pharmaceutical company that develops and markets treatments in women's health, endocrinology, and consumer healthcare. Founded in 1996, the company has a strong focus on pioneering solutions and making them accessible worldwide. Key product areas include emergency contraception (e.g., ellaOne®), blister care (e.g., Compeed®), and treatments for rare diseases. In 2021, HRA Pharma was acquired by Perrigo Company plc, a leading provider of Consumer Self-Care Products, significantly expanding Perrigo's portfolio and global reach in these critical healthcare segments.
Serves as a key operational hub for HRA Pharma's activities, including strategic planning, product development oversight, and European market coordination within the Perrigo group.
Modern office facilities located in a business district accessible to Paris, designed to support a dynamic and innovative pharmaceutical team.
The culture likely emphasizes innovation, scientific rigor, patient-centricity, and collaboration. Post-acquisition by Perrigo, there would be an ongoing integration with Perrigo's broader corporate culture focused on self-care and consumer health.
Historically the nerve center for HRA Pharma's global expansion and product innovation before its acquisition. It remains a significant site for Perrigo's Consumer Self-Care International (CSCI) operations.
As part of Perrigo, HRA Pharma's products are distributed in over 90 countries worldwide. Its global presence is supported by a network of regional offices, distributors, and partners. Functions supported globally include research and development collaborations, manufacturing oversight (often via contract manufacturing organizations), quality assurance, regulatory affairs, supply chain management, and international marketing and sales operations, particularly strong in Europe and expanding in other key international markets.
200 Avenue de Paris
Châtillon
Île-de-France
France
Address: Haines House, 21 John Street, London, WC1N 2BF, UK
Serves the UK market by ensuring availability and compliance of women's health, rare disease, and consumer healthcare products, tailoring strategies to local needs.
Address: Via Giovanni Spadolini 7, Centro Leoni, Edificio B, 20141 Milano, Italy
To effectively deliver HRA Pharma's healthcare solutions to patients and consumers in Italy, adapting to local healthcare system requirements and consumer preferences.
Address: Paseo de la Castellana 259C, Torre de Cristal, Planta 18, 28046 Madrid, Spain
Ensures that HRA Pharma's innovative treatments reach the Spanish population, managing local partnerships and regulatory landscapes.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, HRA Pharma' leadership includes:
HRA Pharma has been backed by several prominent investors over the years, including:
Significant executive changes at Perrigo, HRA Pharma's parent company, often influence the strategic direction of its subsidiaries. In the last year, the most notable change was at the CEO level of Perrigo.
Discover the tools HRA Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Perrigo, HRA Pharma likely used email formats such as [first_initial][last]@hra-pharma.com or [first].[last]@hra-pharma.com. Post-acquisition, many employees may have transitioned to Perrigo's email system (e.g., @perrigo.com), though legacy HRA Pharma addresses might still be in use for some or for a transitional period.
[first_initial][last]@hra-pharma.com or [first_initial][last]@perrigo.com
Format
jdoe@hra-pharma.com or jdoe@perrigo.com
Example
70%
Success rate
Perrigo Investor Relations • May 7, 2024
Perrigo reported its Q1 2024 results, highlighting strong organic net sales growth. The Consumer Self-Care International segment, which includes brands acquired from HRA Pharma, contributed to this performance, demonstrating continued consumer demand for these products....more
Perrigo Company plc News • September 8, 2021
Perrigo Company plc announced the successful completion of its acquisition of HRA Pharma for €1.8 billion. This strategic move significantly enhances Perrigo's self-care offerings and expands its global footprint, particularly in women's health and consumer healthcare....more
Fierce Pharma • July 15, 2022
Perrigo is leveraging its marketing capabilities for Opill, a daily birth control pill developed by HRA Pharma, which was submitted to the FDA for over-the-counter (OTC) status. This highlights the strategic value of HRA Pharma's pipeline to Perrigo....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including HRA Pharma, are just a search away.